FLUTIZING® – S 250

407.81

Composition: Fluticasone Propionate 250 mcg & Salmeterol Xinafoate 50 mcg

Packing: 30 Rotacaps

Category:

FLUTIZING S 250 Dry Powder Inhaler combines Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg to support the long-term management of respiratory conditions associated with airway inflammation and bronchoconstriction. Fluticasone helps reduce inflammation within the airways, while Salmeterol provides prolonged bronchodilation by relaxing airway muscles. Available as 30 Rotacaps, the medication delivers targeted therapy directly to the lungs through a compatible dry powder inhaler device, helping improve breathing comfort and respiratory control under medical supervision.

Contact Us

FLUTIZING S 250 Dry Powder Inhaler is a combination respiratory medication formulated with Fluticasone Propionate, an inhaled corticosteroid, and Salmeterol Xinafoate, a long-acting beta₂-agonist bronchodilator. This dual-action therapy is designed to help manage chronic respiratory conditions where both airway inflammation and airway narrowing contribute to breathing difficulties.

Fluticasone works by reducing swelling and inflammation within the airways, helping decrease airway sensitivity and irritation. Salmeterol complements this action by relaxing the smooth muscles surrounding the airways, allowing them to remain open for an extended period and supporting easier breathing.

The medication is supplied as Rotacaps, which are intended to be used with a compatible dry powder inhaler device. This method allows direct delivery of the medication into the lungs, promoting effective local action while supporting long-term respiratory management. With regular use as prescribed, FLUTIZING S 250 may help improve breathing comfort, reduce wheezing, minimize chest tightness, and support overall respiratory health.

Indications / Uses

FLUTIZING S 250 Dry Powder Inhaler is indicated for the maintenance management of chronic respiratory conditions associated with airway inflammation and bronchoconstriction.

The combination of Fluticasone Propionate and Salmeterol Xinafoate helps provide anti-inflammatory action together with prolonged bronchodilation, supporting improved airflow and better respiratory function.

Regular use may help manage symptoms such as:

  • Persistent wheezing
  • Chronic cough
  • Chest tightness
  • Shortness of breath
  • Airway inflammation

FLUTIZING S 250 is intended for long-term maintenance therapy and should be used consistently as prescribed by a healthcare professional.

How It Works

FLUTIZING S 250 Dry Powder Inhaler combines two well-established respiratory medicines that work through complementary mechanisms.

Fluticasone Propionate is an inhaled corticosteroid that reduces airway inflammation by decreasing inflammatory activity and swelling inside the respiratory passages. This helps reduce airway sensitivity and supports easier airflow.

Salmeterol Xinafoate is a long-acting bronchodilator that stimulates beta₂ receptors in the airway muscles, causing them to relax. This widens the air passages and helps maintain easier breathing for an extended duration.

Delivered through a dry powder inhaler device, the medication reaches the lungs directly, allowing targeted respiratory therapy and helping maintain long-term respiratory control.

Benefits

FLUTIZING S 250 Dry Powder Inhaler provides dual-action respiratory support by combining an inhaled corticosteroid with a long-acting bronchodilator.

Regular use may help:

  • Reduce airway inflammation
  • Improve airflow to the lungs
  • Decrease wheezing and breathlessness
  • Minimize chest tightness and coughing
  • Support long-term respiratory stability
  • Improve day-to-day breathing comfort
  • Enhance overall quality of life through better symptom control

The dry powder formulation enables direct delivery of medication to the lungs while reducing systemic exposure.

Dosage & Administration

FLUTIZING S 250 Dry Powder Inhaler should be used exactly as prescribed by a qualified healthcare professional.

The Rotacap should be inserted into a compatible dry powder inhaler device according to the manufacturer’s instructions. Once loaded, inhale the medication deeply and steadily through the mouthpiece to ensure effective delivery into the lungs.

Patients should never swallow the Rotacap.

After every dose, patients are advised to rinse their mouth thoroughly with water and spit it out. This helps reduce the risk of oral fungal infections and throat irritation associated with inhaled corticosteroids.

The dosage and treatment duration depend on the patient’s respiratory condition and clinical response.

Precautions & Warnings

Before using FLUTIZING S 250 Dry Powder Inhaler, patients should inform their healthcare professional about any existing medical conditions, especially heart disease, hypertension, diabetes, liver disorders, glaucoma, thyroid disorders, osteoporosis, tuberculosis, respiratory infections, or known hypersensitivity to any component of the medication.

FLUTIZING S 250 is intended for maintenance therapy and should not be used as the sole treatment for sudden breathing emergencies. Patients should continue carrying their prescribed rescue medication for immediate symptom relief when necessary.

Regular medical follow-up is recommended, particularly during prolonged therapy. Pregnant or breastfeeding women should use the medication only under medical advice.

Side Effects

Like all medications, FLUTIZING S 250 Dry Powder Inhaler may cause side effects, although many patients tolerate treatment well.

Common side effects may include:

  • Throat irritation
  • Hoarseness
  • Dry mouth
  • Headache
  • Cough
  • Oral thrush
  • Mild tremors
  • Palpitations

Less commonly, some individuals may experience muscle cramps, dizziness, nervousness, or changes in heart rate.

Seek immediate medical attention if symptoms such as allergic reactions, worsening breathing difficulties, severe chest pain, or facial swelling occur.

Drug Interactions

Before using FLUTIZING S 250 Dry Powder Inhaler, patients should inform their healthcare provider about all prescription medicines, over-the-counter drugs, vitamins, herbal supplements, and nutritional products they are currently taking.

Special caution may be required when the medication is used together with:

  • Beta-blockers
  • Antifungal medicines
  • Certain antibiotics
  • Diuretics
  • Antidepressants
  • Other long-acting bronchodilators
  • Medicines affecting heart rhythm

Patients should not modify their medication regimen without consulting their healthcare professional.

Storage Instructions

Store FLUTIZING S 250 Dry Powder Inhaler in a cool and dry place below 25°C.

Keep the Rotacaps in their original blister packaging until immediately before use to protect them from moisture and environmental exposure.

Avoid excessive heat, humidity, and direct sunlight. Do not freeze.
Keep out of reach of children and pets. Do not use damaged or expired Rotacaps.

Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult a qualified healthcare professional before using any medication.

Frequently Asked Questions (FAQs)

FLUTIZING S 250 Dry Powder Inhaler is prescribed for the long-term management of respiratory conditions involving airway inflammation and bronchoconstriction. It helps improve breathing and supports better day-to-day respiratory control when used regularly.
FLUTIZING S 250 Dry Powder Inhaler contains Fluticasone Propionate, which reduces airway inflammation, and Salmeterol Xinafoate, which provides prolonged bronchodilation. Together, they address two important factors that contribute to chronic respiratory symptoms.
No, FLUTIZING S 250 Dry Powder Inhaler is designed for maintenance therapy and should not replace a rescue inhaler during sudden breathing emergencies. Patients should always follow their healthcare professional's emergency treatment plan.
Rinsing the mouth after using FLUTIZING S 250 Dry Powder Inhaler helps reduce the likelihood of oral fungal infections (thrush), throat irritation, and hoarseness that may occur with inhaled corticosteroid therapy.
FLUTIZING S 250 Rotacaps should only be used with a compatible dry powder inhaler device. The Rotacap should never be swallowed, chewed, or opened manually, as the medication is intended to be inhaled directly into the lungs.
FLUTIZING S 250 Dry Powder Inhaler may be recommended for patients who require both anti-inflammatory treatment and long-acting bronchodilation for persistent respiratory symptoms. The decision to prescribe the medication should always be made by a healthcare professional.
Regular use of FLUTIZING S 250 Dry Powder Inhaler may help reduce airway inflammation, improve airflow, decrease respiratory symptoms, minimize flare-ups, and support long-term respiratory stability when taken as prescribed.
Store FLUTIZING S 250 Dry Powder Inhaler below 25°C in its original blister packaging, away from moisture, direct sunlight, and excessive heat. Keep the Rotacaps sealed until they are ready for use to maintain their quality and effectiveness.